Ensoma key facts
as of Oct 2026- Operator of a biotech company intended to develop a genomic medicine in vivo approach to engineer any or all blood and immune cells to cure diseases.
- Ensoma is valued at approximately $280.0M as of Oct 2026 (last reported valuation).
- It has raised $258.0M across 3 recorded rounds; the latest was Later Stage VC (Series B1) ($53.0M) in Sep 2025.
- Notable investors include Viking Global Investors, F-Prime Capital, Alexandria Venture Investments, Gates Foundation, Qatar Investment Authority — 21 tracked in total.
- Ensoma has filed 3 Form Ds with the SEC since 2021, most recently May 2023 ($129.0M sold to 22 investors).
- Status: Privately Held (backing).
Ensoma's last reported valuation, May 2023. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Ensoma: the Monday email on marks, rounds and moves
Ensoma funding rounds
3 roundsWho backs Ensoma
21+Ensoma valuation
Ensoma's last reported valuation was $280 million in May 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Ensoma raised?
Ensoma has raised $258 million across 3 recorded rounds since 2021. The largest was a $70 million Series A in Feb 2021; the most recent was a $53 million Series B1 in Sep 2025.
Ensoma has filed 3 Form Ds with the SEC since 2021, most recently in May 2023 ($129 million sold to 22 investors).
Ensoma investors
21 investors are on record for Ensoma, including Viking Global Investors, F-Prime Capital, Alexandria Venture Investments and Gates Foundation. By type, the record holds 4 venture capital firms and 3 asset managers. The Series B1 in Sep 2025 drew 14 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Mythic Therapeutics ($293 million), City Therapeutics ($285 million) and Convergent Therapeutics ($280 million).
About Ensoma
Operator of a biotech company intended to develop a genomic medicine in vivo approach to engineer any or all blood and immune cells to cure diseases. The company focuses on engineered vectors that permit to delivery of gene modification technologies directly to stem cells or the various cell types that arise from these cells, such as T cells, B cells, and myeloid cells, without the need for stem cell collection or prior conditioning, which can be toxic to patients, enabling health professionals to have access to genomic medicines that can be delivered in a single injection.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 67
- Website
- ensoma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.